• AR/ARv7 Targeting in TNBC: EPI-001 Evidence

  2026-10-01

  This 2025 study connects AR and ARv7 expression with adverse outcomes in triple-negative breast cancer (TNBC) and tests Enzalutamide and EPI-001 in the MDA-MB-231 model. Its main contribution is the integration of patient biomarker data, TCGA analysis, migration assays, and EMT-related molecular readouts to show how AR/ARv7 blockade may suppress invasive phenotypes.

• EPI-001: Beyond Ligand-Binding AR Targeting

  2026-10-01

  EPI-001 is an androgen receptor N-terminal domain inhibitor that enables translational studies of ligand-independent AR biology, castration-resistant prostate cancer, and AR/ARv7-driven metastatic programs in triple-negative breast cancer. This thought-leadership perspective connects mechanism, experimental design, competitive positioning, and biomarker strategy.

• RWJ 67657: Reading p38 Signaling More Precisely

  2026-10-01

  RWJ 67657, also known as JNJ-3026582, is a selective p38α/β inhibitor for dissecting cytokine biology. This article translates recent p38α structural findings into practical assay strategies that separate kinase blockade, phosphatase-driven dephosphorylation, and downstream TNF responses.

• ST3GAL1, Sialylation, and F. nucleatum Adhesion in CRC

  2026-09-30

  The reference study identifies ST3GAL1-mediated sialylation as a host determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. Its perturbation experiments further connect bacterial persistence and tumor-promoting activity with an H3K27ac/ANGPTL4 axis, offering a mechanistic framework for studying intratumoral microbial retention.

• EPI-001: AR N-Terminal Domain Inhibition

  2026-09-29

  Build ligand-independent androgen receptor assays that distinguish N-terminal blockade from conventional ligand-binding-domain inhibition. This guide translates prostate cancer and ARv7 findings into practical cell-based workflows, controls, and troubleshooting strategies for translational research.

• Ruxolitinib Phosphate: From JAK Signals to Cell Fate

  2026-09-29

  Ruxolitinib phosphate (INCB018424) is a selective JAK1/JAK2 research tool that connects cytokine signaling inhibition with mitochondrial control of cell fate. This thought-leadership article translates evidence from anaplastic thyroid carcinoma into practical guidance for oncology, rheumatoid arthritis research, and autoimmune disease models while defining the limits of cross-domain interpretation.

• Alkaline Phosphatase (AP) Substrate Test Kit

  2026-09-28

  The Alkaline Phosphatase (AP) Substrate Test Kit provides BCIP/NBT color development for visualizing alkaline phosphatase activity in Western blotting, immunohistochemistry, membrane assays, and selected iPS workflows. It is intended for scientific research use only and should not be used as a diagnostic, medical, fluorescent, or independently quantitative assay.

• Oltipraz Workflows for Nrf2 and Liver Stress Research

  2026-09-28

  Use Oltipraz to test whether Nrf2-linked phase II enzyme induction changes cellular responses to xenobiotic or liver stress. This practical workflow connects the compound’s established enzyme-induction profile with a recent MASLD study, while clearly separating shared pathway rationale from untested treatment claims.

• CDC42 Supports HBV Entry via NTCP and Macropinocytosis

  2026-09-27

  The study identifies CDC42 as a regulator of hepatitis B virus (HBV) entry through two separable effects: promoting NTCP delivery to the cell surface and supporting macropinocytosis. Its findings refine the current model of HBV uptake by distinguishing this CDC42-dependent route from clathrin-mediated endocytosis, while raising questions about how broadly the mechanism applies across infection models.

• 2-Thio-dCTP for Reliable DNA Assay Workflows

  2026-09-26

  Learn where 2-Thio-dCTP (SKU B8104) can support controlled DNA synthesis and where it should not be mistaken for a direct cell-viability reagent. This scenario-based guide covers experimental fit, handling, interpretation, and evidence-aware product selection.

• 5-Azacytidine and Viral Mimicry in PTEN-Deficient GBM

  2026-09-25

  5-Azacytidine is more than a DNA methylation tool: in PTEN-deficient glioblastoma, its immune effects depend on chromatin context. This article explains a recent EZH2-combination study and translates its findings into practical assay-design decisions.

• Cyclosporin A B1922: Reliable Cell Assay Design

  2026-09-25

  A practical guide to using Cyclosporin A (SKU B1922) in cell viability, proliferation, and cytotoxicity workflows. It covers mechanism, solvent and storage considerations, starting conditions, interpretation limits, and evidence-based product selection.

• Doxycycline in 3D Stem Cell Mechanobiology

  2026-09-24

  Use Doxycycline as a carefully controlled probe of metalloproteinase-dependent matrix remodeling—not as a stand-in for the rapid cell tumbling that drives stem cell fate in sliding hydrogels. This workflow pairs dose and vehicle controls with live imaging and differentiation readouts to help distinguish matrix effects from drug-related changes in cell health.

• EPI-001 Workflows for AR Signaling Research

  2026-09-24

  EPI-001 lets researchers probe androgen receptor activity through its N-terminal domain, including signaling that may persist when the ligand-binding domain is absent. This workflow connects dose-response and transcriptional assays with migration readouts, while distinguishing established product data from proposed starting conditions and exploratory TNBC applications.

• EPI-001 in TNBC: Reading ARv7 Evidence Carefully

  2026-09-24

  EPI-001 is an androgen receptor N-terminal domain inhibitor with a distinct research rationale in triple-negative breast cancer. This article examines what recent AR/ARv7 findings mean for interpreting migration and EMT assays—and where the evidence still stops short.

8596 records 1/574 page Next 12345 下5页 Last page